KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Short-term Investments (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Short-term Investments for 9 consecutive years, with $185.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments fell 14.4% year-over-year to $185.0 million, compared with a TTM value of $185.0 million through Dec 2025, down 14.4%, and an annual FY2025 reading of $185.0 million, down 14.4% over the prior year.
  • Short-term Investments was $185.0 million for Q4 2025 at Biocryst Pharmaceuticals, up from $128.8 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $278.3 million in Q4 2023 and bottomed at $128.8 million in Q3 2025.
  • Average Short-term Investments over 3 years is $216.9 million, with a median of $224.7 million recorded in 2024.
  • The sharpest move saw Short-term Investments increased 3.79% in 2024, then crashed 44.76% in 2025.
  • Year by year, Short-term Investments stood at $278.3 million in 2023, then fell by 22.35% to $216.1 million in 2024, then dropped by 14.4% to $185.0 million in 2025.
  • Business Quant data shows Short-term Investments for BCRX at $185.0 million in Q4 2025, $128.8 million in Q3 2025, and $172.0 million in Q2 2025.